What is the role of ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria (PNH)?

Updated: May 20, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print

In both C5 inhibitor–naïve PNH patients and those previously treated with eculizumab, ravulizumab (Ultomiris) has proved non-inferior to eculizumab across all efficacy endpoints. [37, 38, 43]  In addition, ravulizumab has a low incidence of breakthrough hemolysis compared with eculizumab. [44, 45, 46]  Because of this lower incidence, ravulizumab has been shown to be more cost-effective than eculizumab. Patient acceptance is also high, because of the less-frequent dosing. [46, 47, 48]  

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!